Lin Aihua, Liu Yiming, Huang Yu, Sun Jingbo, Wu Zhifeng, Zhang Xian, Ping Qineng
Department of Pharmaceutical Technology, Faculty of Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 210009, People's Republic of China.
Int J Pharm. 2008 Jul 9;359(1-2):247-53. doi: 10.1016/j.ijpharm.2008.03.039. Epub 2008 Apr 4.
The aim of the present work was to investigate the potential utility of chitosan nanoparticles surface modified with glycyrrhizin (CS-NPs-GL) as new hepatocyte-targeted delivery vehicles. For this purpose, chitosan nanoparticles (CS-NPs) were prepared previously by ionic gelation process and glycyrrhizin was oxidized by sodium periodate to be conjugated to the surface of CS-NPs. The CS-NPs-GL obtained were first characterized for their morphology, particle size, zeta potential, association efficiency and in vitro release of adriamycin (ADR), using as a model drug. The nanoparticles were also labeled with rhodamine B isothiocyanate and their interaction with rat hepatocytes was examined by flow cytometry (FCM) and confocal laser microscopy (CLSM). The spherical nanoparticles prepared with oxidized GL/CS ratio of 0.14:1 (w/w) were in the 147.2nm size range, and exhibited a positive electrical charge (+9.3mV), and associated ADR quite efficiently (association efficiency: 91.7%) and showed lower extent of release (28% over 72h) in vitro. FCM and CLSM studies showed that CS-NPs-GL were preferentially accumulated in hepatocytes and the cellular uptake amount were 4.9 times more than that in hepatic nonparenchymal cells, and the uptake process was dependent on incubation time and dose of nanoparticles, which indicated that the internalization of these nanoparticles into hepatocytes was mostly mediated by a ligand-receptor interaction. In conclusion, CS-NPs-GL as a promising hepatocyte-targeted delivery carrier holds promise for further effective studies.
本研究的目的是探讨用甘草酸修饰的壳聚糖纳米粒(CS-NPs-GL)作为新型肝细胞靶向给药载体的潜在效用。为此,先前通过离子凝胶法制备了壳聚糖纳米粒(CS-NPs),并用高碘酸钠氧化甘草酸以使其与CS-NPs表面偶联。首先对所得的CS-NPs-GL进行表征,包括其形态、粒径、zeta电位、结合效率以及作为模型药物的阿霉素(ADR)的体外释放。还用异硫氰酸罗丹明对纳米粒进行标记,并通过流式细胞术(FCM)和共聚焦激光显微镜(CLSM)检查其与大鼠肝细胞的相互作用。氧化GL/CS比例为0.14:1(w/w)制备的球形纳米粒尺寸范围为147.2nm,带正电荷(+9.3mV),能高效结合ADR(结合效率:91.7%),且在体外显示出较低的释放程度(72小时内释放28%)。FCM和CLSM研究表明,CS-NPs-GL优先在肝细胞中积累,细胞摄取量比肝非实质细胞高4.9倍,摄取过程取决于纳米粒的孵育时间和剂量,这表明这些纳米粒进入肝细胞的内化过程主要由配体-受体相互作用介导。总之,CS-NPs-GL作为一种有前景的肝细胞靶向给药载体,有望进行进一步的有效研究。
J Pharm Pharmacol. 2014-8
Yao Xue Xue Bao. 2007-7
Yao Xue Xue Bao. 2007-3
Int J Pharm. 2009-4-15
J Control Release. 2008-12-8
Drug Deliv Transl Res. 2025-6
Nanomaterials (Basel). 2023-12-26
Front Cell Infect Microbiol. 2021
Nanomaterials (Basel). 2020-4-30